BWG
ESPR

Boomfish Wealth Group’s Esperion Therapeutics ESPR Stock Holding History

Boomfish Wealth Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$143K Hold
45,306
– – 0.07% 94
2026
Q1 		$124K Hold
45,306
– – 0.07% 86
2025
Q4 		$168K Hold
45,306
– – 0.09% 85
2025
Q3 		$120K Hold
45,306
– – 0.06% 87
2025
Q2 		$44.6K Buy
45,306
+10,309
+29% +$10.3K 0.03% 87
2025
Q1 		$50.4K Hold
34,997
– – 0.03% 82
2024
Q4 		$77K Hold
34,997
– – 0.05% 93
2024
Q3 		$57.7K Buy
34,997
+5,102
+17% +$10.3K 0.04% 89
2024
Q2 		$66.4K Hold
29,895
– – 0.04% 86
2024
Q1 		$80.1K Buy
+29,895
New +$72.6K 0.05% 87

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Boomfish Wealth Group's ESPR Position: Q2 2026 in Review

Boomfish Wealth Group held its Esperion Therapeutics (ESPR) position steady in Q2 2026 at 45,306 shares worth $143K. The position accounts for 0.07% of the portfolio, ranked #94.

Boomfish Wealth Group first reported a position in ESPR in Q1 2024 and has held it in 10 quarters since. The position peaked at $168K in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Boomfish Wealth Group held 45,306 shares of Esperion Therapeutics worth $143K as of Q2 2026.
  • Boomfish Wealth Group left its Esperion Therapeutics share count unchanged in Q2 2026.
  • Esperion Therapeutics made up 0.07% of Boomfish Wealth Group's portfolio in Q2 2026, its #94 holding.
  • Boomfish Wealth Group first reported a position in Esperion Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Boomfish Wealth Group's Esperion Therapeutics position peaked at $168K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Boomfish Wealth Group's 13F filing for Q2 2026, filed 4 Aug 2026.